**CLAIMS**

1. Use of a therapeutically effective amount of a compound represented by the formula:




or a pharmaceutically acceptable salt thereof, wherein

A is $C_5$ alkyl, $C_6$ alkyl, $C_5$ alkenyl, $C_6$ alkenyl, $C(O)-(CH_2)_n-CH_3$ or $CH(OH)-(CH_2)_n-CH_3$ wherein n is 3 or 4;

$R_1$ is H, OH or F;

$R_2$ is H, OH, F or $CH_2$-OH;

$R_3$ is H, OH, F or $CH_2Ph$;

$R_4$ is H, OH or F;

Q is

1) $(CH_2)_mC(O)OH$ wherein m is 1 or 2,

2) CH(F)-C(O)OH,

3) $CF_2$-C(O)OH, or

4) C(O)-C(O)OH; in the manufacture of a medicament for preventing and/or slowing progression of and/or treating ~~a fibrotic disease~~fibrosis in a subject in need thereof, wherein the subject suffers from a fibrotic disease ~~is~~ selected from pulmonary fibrosis, liver fibrosis, skin fibrosis or cardiac fibrosis.

2. The use according to claim 1, wherein the pharmaceutically acceptable salt of said compound is sodium, potassium, lithium, ammonium, calcium, magnesium, manganese, zinc, iron, or copper.

18. The use according to claim 14, wherein the skin fibrosis is scarring, hypertrophic scarring, keloid scarring, dermal fibrotic disorder, wound healing, delayed wound healing, psoriasis or scleroderma.

19. The use of claim 18, wherein said scarring derives from a wound, a burn, a scar, wrinkles, stretch marks, sun damage, chemical damage, heat damage, cold damage, a trauma, a surgical injury, a radiation or an ulcer. 20. The method of claim 19, wherein said ulcer is diabetic foot ulcer, venous leg ulcer or pressure ulcer.

21. The use according to any one of claims 1-4, wherein the fibrotic disease is cardiac fibrosis.

22. The use of claim 21, wherein the cardiac fibrosis is cardiomyopathy, congestive heart failure.

23. Use of a therapeutically effective amount of a compound as defined in any one of claims 1-4, in the manufacture of a medicament for antagonizing collagen secretion or collagen deposition in an organ of a mammal, wherein the organ is lung, liver, skin or heart.

24. Use of a therapeutically effective amount of a compound as defined in any one of claims 1-4 in the manufacture of a medicament for reducing the collagen production in cells, wherein said compound is to be contacted with the cells.

25. The use according to any one of claims 1-22, wherein the compound is to be administered in combination with a therapeutically effective amount of second compound, the second compound is an immunosuppressive drug, an anti-inflammatory drug, a cytokine, a monoclonal antibody, a multiple receptor tyrosine kinase inhibitor, an antioxidant, an enzyme inhibitor, an integrin inhibitor, a lipid receptor modulator or a thiazolindione.

26. The use according to claim 25, wherein the fibrotic disease is pulmonary fibrosis, and wherein the compound is administered in combination with a therapeutically effective amount of pirfenidone.

27. The use according to any one of claims 5 to 8, wherein the compound is to be administered in combination with a therapeutically effective amount of nintedanib.

~~27~~28. A kit for preventing and/or slowing progression of and/or treating ~~fibrotic disease~~fibrosis in a subject in need thereof, comprising a compound represented by the formula:




or a pharmaceutically acceptable salt thereof, wherein

A is $C_5$ alkyl, $C_6$ alkyl, $C_5$ alkenyl, $C_6$ alkenyl, $C(O)-(CH_2)_n-CH_3$ or $CH(OH)-(CH_2)_n-CH_3$ wherein n is 3 or 4;

$R_1$ is H, OH or F;

$R_2$ is H, OH, F or $CH_2$-OH;

$R_3$ is H, OH, F or $CH_2Ph$;

$R_4$ is H, OH or F;

Q is

1) $(CH_2)_mC(O)OH$ wherein m is 1 or 2,
2) $CH(CH_3)C(O)OH$,
3) $C(CH_3)_2C(O)OH$,
4) CH(F)-C(O)OH,
5) $CF_2$-C(O)OH, or
6) C(O)-C(O)OH;

and instructions for administering a therapeutically effective amount of the compound to the subject suffering from fibrosis, wherein the subject suffers from a ~~said~~ fibrotic disease~~, wherein the fibrotic disease is~~selected from pulmonary fibrosis, liver fibrosis, skin fibrosis or cardiac fibrosis.

~~28~~29. The kit of claim ~~27~~28, further comprises instructions for administering between about 1 to about 50 mg/kg of the compound daily and orally to the subject who is a human.

2930. The kit of claim 2728, further comprises instructions for administering between about 0.01 to about 10 % (w/w) of the compound daily and topically to the subject who is a human, and wherein the fibrotic disease is skin fibrosis.

3031. A compound represented by the formula:




or a pharmaceutically acceptable salt thereof, wherein

A is $C_5$ alkyl, $C_6$ alkyl, $C_5$ alkenyl, $C_6$ alkenyl, $C(O)-(CH_2)_n-CH_3$ or $CH(OH)-(CH_2)_n-CH_3$ wherein n is 3 or 4;

$R_1$ is H, OH or F;

$R_2$ is H, OH, F or $CH_2$-OH;

$R_3$ is $CH_2Ph$;

$R_4$ is H, OH or F;

Q is

1) $(CH_2)_mC(O)OH$ wherein m is 1 or 2,

2) $CH(CH_3)C(O)OH$,

3) $C(CH_3)_2C(O)OH$,

4) CH(F)-C(O)OH,

5) $CF_2$-C(O)OH, or

6) C(O)-C(O)OH.

~~31~~32. The compound of claim ~~30~~31, wherein the compound is:

| | |
|---|---|
| Compound XX |  |